I. Fumagalli

Papers

Total Citations

H-Index

About

I. Fumagalli is a radiation oncologist whose research centers on stereotactic body radiation therapy (SBRT) for hepatic tumors, with a particular focus on improving local control outcomes for both primary liver cancers and metastatic lesions. Their major contribution lies in identifying key prognostic factors that influence treatment success following robotic SBRT with real-time tumor tracking. In their most cited work (68 citations), Fumagalli demonstrated that factors such as tumor size, dose prescription, and lesion type significantly impact local control rates, providing clinicians with evidence-based parameters to optimize patient selection and radiation planning. Their 2011 study detailing the Lille experience further established SBRT as a safe and effective modality for liver malignancies, achieving low toxicity while maintaining efficacy. By systematically analyzing treatment outcomes, Fumagalli has helped refine SBRT protocols, enabling more precise tumor targeting and better sparing of healthy liver tissue. This work has practical implications for patients with inoperable hepatic tumors, offering a non-invasive alternative with durable local control. Fumagalli’s research continues to shape clinical decision-making in liver SBRT, bridging the gap between technological innovation and patient-centered care.